128 related articles for article (PubMed ID: 33507729)
1. Long-Term Near-Infrared Signal Tracking of the Therapeutic Changes of Glioblastoma Cells in Brain Tissue with Ultrasound-Guided Persistent Luminescent Nanocomposites.
Cheng CL; Chan MH; Feng SJ; Hsiao M; Liu RS
ACS Appl Mater Interfaces; 2021 Feb; 13(5):6099-6108. PubMed ID: 33507729
[TBL] [Abstract][Full Text] [Related]
2. An Advanced
Chan MH; Chen W; Li CH; Fang CY; Chang YC; Wei DH; Liu RS; Hsiao M
ACS Appl Mater Interfaces; 2021 Jun; 13(23):26759-26769. PubMed ID: 34076419
[TBL] [Abstract][Full Text] [Related]
3. Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy.
Du K; Xia Q; Sun J; Feng F
ACS Appl Mater Interfaces; 2021 Dec; 13(47):55851-55861. PubMed ID: 34788006
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
Bikhezar F; de Kruijff RM; van der Meer AJGM; Torrelo Villa G; van der Pol SMA; Becerril Aragon G; Gasol Garcia A; Narayan RS; de Vries HE; Slotman BJ; Denkova AG; Sminia P
J Neurooncol; 2020 Jan; 146(2):239-246. PubMed ID: 31875307
[TBL] [Abstract][Full Text] [Related]
5. A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin.
Prabhu S; Goda JS; Mutalik S; Mohanty BS; Chaudhari P; Rai S; Udupa N; Rao BSS
Nanoscale; 2017 Aug; 9(30):10919-10932. PubMed ID: 28731079
[TBL] [Abstract][Full Text] [Related]
6. Studies examining the synergy between Dihydrotanshinone and Temozolomide against MGMT+ glioblastoma cells in vitro: Predicting interactions with the blood-brain barrier.
Kumar V; Radin D; Leonardi D
Biomed Pharmacother; 2019 Jan; 109():386-390. PubMed ID: 30399573
[TBL] [Abstract][Full Text] [Related]
7. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
8. Carnosine increases efficiency of temozolomide and irradiation treatment of isocitrate dehydrogenase-wildtype glioblastoma cells in culture.
Dietterle J; Oppermann H; Glasow A; Neumann K; Meixensberger J; Gaunitz F
Future Oncol; 2019 Nov; 15(32):3683-3691. PubMed ID: 31664860
[No Abstract] [Full Text] [Related]
9. Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.
Yamamoto Y; Sasaki N; Kumagai K; Takeuchi S; Toyooka T; Otani N; Wada K; Narita Y; Ichimura K; Namba H; Mori K; Tomiyama A
Neurol Med Chir (Tokyo); 2018 Jul; 58(7):296-302. PubMed ID: 29899179
[TBL] [Abstract][Full Text] [Related]
10. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
11. Piezoelectric barium titanate nanostimulators for the treatment of glioblastoma multiforme.
Marino A; Almici E; Migliorin S; Tapeinos C; Battaglini M; Cappello V; Marchetti M; de Vito G; Cicchi R; Pavone FS; Ciofani G
J Colloid Interface Sci; 2019 Mar; 538():449-461. PubMed ID: 30537658
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
14. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W
Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.
Oancea-Castillo LR; Klein C; Abdollahi A; Weber KJ; Régnier-Vigouroux A; Dokic I
Cancer Biol Ther; 2017 Jun; 18(6):400-406. PubMed ID: 28494176
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy.
Du K; Xia Q; Heng H; Feng F
ACS Appl Mater Interfaces; 2020 Aug; 12(31):34599-34609. PubMed ID: 32648735
[TBL] [Abstract][Full Text] [Related]
17. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
19. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells.
Mazor G; Levin L; Picard D; Ahmadov U; Carén H; Borkhardt A; Reifenberger G; Leprivier G; Remke M; Rotblat B
Cell Death Dis; 2019 Mar; 10(3):246. PubMed ID: 30867410
[TBL] [Abstract][Full Text] [Related]
20. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]